EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
Geert R. D'Haens 1
Peter D.R. Higgins 2
Laurent Peyrin-Biroulet 3
Bruce E. Sands 4
Scott D. Lee 5
Richard Moses 6
Isabel Redondo 7
Rodrigo Escobar 8
Nathan Morris 8
Taku Kobayashi 9
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
2 University of Michigan, Ann Arbor, United States
3 University Hospital of Nancy, Vandoeuvre-les-Nancy, France
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 University of Washington Medical Center, Seattle, United States
6 Eli Lilly and Company, Indianapolis, United States
7 Eli Lilly Portugal, Lisbon, Portugal
8 Lilly S.A., Alcobendas, Spain
9 Kitasato University Kitasato Institute Hospital, Minato-ku, Japan
Topic
Endoscopy, Histopathology, IBD
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]